Poplar Grove Pharmacy Inc.;, 80189-80190 [2020-27234]
Download as PDF
Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices
823(f), I hereby deny the application
submitted by George Pursley, M.D.,
Control No. W15101573C, seeking
registration in Georgia as a practitioner,
and any other pending application
submitted by George Pursley, M.D. for a
DEA registration in the State of Georgia.
This Order is effective January 11, 2021.
Timothy J. Shea,
Acting Administrator.
[FR Doc. 2020–27236 Filed 12–10–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Poplar Grove Pharmacy Inc.;
jbell on DSKJLSW7X2PROD with NOTICES
Decision and Order
On November 20, 2019, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause (hereinafter, OSC) to Poplar
Grove Pharmacy Inc. (hereinafter,
Registrant) of Baltimore, Maryland.
OSC, at 1. The OSC proposed the
revocation of Registrant’s Certificate of
Registration No. FP3109027. Id. It
alleged that Registrant ‘‘has no state
authority to handle controlled
substances.’’ Id. (citing 21 U.S.C.
824(a)(3)).
Specifically, the OSC alleged that,
‘‘[o]n April 15, 2019, the Maryland State
Board of Pharmacy (hereinafter, MBP)
. . . issued an Order for Summary
Suspension, suspending . . .
[Registrant’s] Maryland pharmacy
permit.’’ OSC, at 2. The OSC alleged
that ‘‘[c]onsequently, the DEA must
revoke . . . [Registrant’s] DEA
registration based on . . . [its] lack of
authority to handle controlled
substances in the State of Maryland.’’ Id.
The OSC notified Registrant of the
right to request a hearing on the
allegations or to submit a written
statement, while waiving the right to a
hearing, the procedures for electing each
option, and the consequences for failing
to elect either option. Id. (citing 21 CFR
1301.43). The OSC also notified
Registrant of the opportunity to submit
a corrective action plan. OSC, at 3
(citing 21 U.S.C. 824(c)(2)(C)).
Adequacy of Service
In a sworn Declaration, dated May 22,
2020, a DEA Diversion Investigator
assigned to the Baltimore District Office
(hereinafter, DI) stated that he
accomplished personal service of the
OSC on Susan Nwoga, Registrant’s
registration contact, at the Maryland
Correctional Institution for Women on
VerDate Sep<11>2014
23:25 Dec 10, 2020
Jkt 253001
December 10, 2019. Request for Final
Agency Action (hereinafter, RFAA), EX
4 (DI Declaration), at 1. The DI stated
that Ms. Nwoga took the OSC. Id.
Further evidence of the adequacy of
the Government’s service is Registrant’s
proposed Corrective Action Plan
(hereinafter, CAP) dated December 16,
2019. RFAA EX 5 (CAP), at 1.
Accordingly, based on the evidence in
the RFAA and the Government’s
representations, I find that the
Government’s service of the OSC was
adequate.
Registrant’s Proposed CAP
As already discussed, Registrant
timely submitted a proposed CAP. Id. In
the CAP, Registrant asked that ‘‘DEA
begin an internal investigation on it’s
[sic] failure to provide . . . [Ms. Nwoga]
with whistle blower protection and why
when big retail pharmacies are met with
fines, the DEA set out to entrap . . .
[her], a black woman who is an
American of Nigerian descent.’’ Id. at 4.
Ms. Nwoga ‘‘denied all charges’’ and
stated that she is ‘‘entitled to all
privileges of a licensed pharmacist.’’ 1 Id.
In the CAP, Registrant did not address
the status of its Maryland pharmacy
permit, including whether the MBP
suspended it.
I find that Registrant waived its right
to a hearing and proposed a CAP. I find
that the Assistant Administrator,
Diversion Control Division, denied ‘‘the
request to discontinue or defer
administrative proceedings.’’ RFAA EX
6 (Letter Denying Proposed CAP), at 1.
I also find that the Assistant
Administrator concluded that ‘‘there is
no potential modification of . . . [the
proposed CAP] that could or would alter
. . . [his] decision in this regard.’’ Id. I
agree with the Assistant Administrator’s
CAP-related decisions.
The Government forwarded its RFAA,
along with the evidentiary record, to my
office on May 28, 2020. In its RFAA, the
Government represented that
‘‘Registrant currently lacks authority to
handle controlled substances in the
state of Maryland, the jurisdiction
where it was licensed as a pharmacy
1 Most of Registrant’s CAP concerned Ms.
Nwoga’s allegations about ‘‘the DEA’s . . . failure
to follow their own monitoring policy, thus,
allowing the Baltimore city streets to become
flooded with controlled narcotics.’’ RFAA EX 5, at
2. The CAP stated that she ‘‘satisfied all the
requirements of whistle blower,’’ but ‘‘[r]ather than
protect . . . [her] the DEA began an illegal under
cover [sic] operation that spanned many years’’ and
entrapped her. Id. at 2–3. According to the CAP,
‘‘[t]his case is wrought with very ugly racism, antifeminism, and anti-immigrant overtones in the
Baltimore City DEA. The criminal case is under
appeal and when reviewed by legal experts, the
experts say I will absolutely be released from
prison.’’ Id. at 3.
PO 00000
Frm 00200
Fmt 4703
Sfmt 4703
80189
and where it is registered with DEA.’’
RFAA, at 3. The Government requested
‘‘a Final Order revoking Registrant’s
DEA registration.’’ Id. at 4.
I issue this Decision and Order based
on the record submitted by the
Government in its RFAA, which
constitutes the entire record before me.2
21 CFR 1301.43(e).
Findings of Fact
Registrant’s DEA Registration
Registrant is the holder of DEA
Certificate of Registration No.
FP3109027 at the registered address of
709 Poplar Grove Street, Baltimore, MD
21216. RFAA, EX 1 (Certification of
Registration), at 1. Pursuant to this
registration, Registrant is authorized to
dispense controlled substances in
schedules II through V for the business
activity of retail pharmacy. Id.
Registrant’s registration ‘‘is in a renewal
pending status until the resolution of
administrative proceedings.’’ Id.
The Status of Registrant’s State License
and Registration
The Government submitted a certified
copy of the ‘‘Order for Summary
Suspension’’ concerning Registrant’s
pharmacy permit No. P05639 that the
MBP issued on April 15, 2019. RFAA,
EX 3 (hereinafter, Summary Suspension
Order). According to the Summary
Suspension Order, Registrant’s
pharmacist ‘‘pleaded guilty . . . to
approximately three hundred (300)
counts that included possession with
. . . [the] intent to distribute a
controlled dangerous substance,
Medicaid fraud, and theft.’’ Id. at 5. The
Summary Suspension Order stated that,
‘‘[f]ollowing her conviction, Pharmacist
A was ordered held in jail until the date
of her sentencing.’’ Id. It also stated that
Registrant ‘‘failed to request or submit to
a closing inspection by the . . . [MBP],
as required by . . . [MBP] regulations,
to ensure the proper transfer of
controlled and non-controlled drug
inventory and confidential prescription
records.’’ Id. at 6.
After concluding that ‘‘the public
health, safety, or welfare imperatively
requires emergency action,’’ the MBP
‘‘summarily suspended’’ the permit
issued to Registrant to operate as a
pharmacy in Maryland. Id. The MBP
thus prohibited Registrant from
operating as a pharmacy in Maryland
and ordered the immediate return of all
pharmacy permits to the MBP. Id.
The Government also submitted a
MBP website screen print showing that
Registrant’s pharmacy permit is
2 The
E:\FR\FM\11DEN1.SGM
RFAA includes Registrant’s proposed CAP.
11DEN1
80190
Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices
‘‘suspended.’’ 3 RFAA, EX 7 (State of
Maryland Board of Pharmacy website
Screen Print), at 1.
As already discussed, Registrant’s
proposed CAP did not address the status
of its Maryland pharmacy permit. As
such, the Government’s record evidence
that Registrant’s pharmacy permit was
summarily suspended is not rebutted.
According to Maryland’s online
records, of which I take official notice,
Registrant’s pharmacy permit is still
suspended today.4 State of Maryland
Board of Pharmacy Web Lookup/
Verification, https://
mdbop.mylicense.com/Verification (last
visited date of signature of this Order).
In sum, there is no record evidence
rebutting the evidence the Government
submitted with its RFAA, EX 3 and EX
7, and the evidence from today’s
Maryland online records supports the
Government’s evidence. Accordingly, I
find that Registrant’s Maryland
pharmacy permit is currently
suspended.
jbell on DSKJLSW7X2PROD with NOTICES
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823 of the CSA ‘‘upon a
finding that the registrant . . . has had
his State license or registration
suspended . . . [or] revoked . . . by
competent State authority and is no
longer authorized by State law to engage
in the . . . dispensing of controlled
substances.’’ With respect to a
practitioner, the Agency has long stated
that the possession of authority to
dispense controlled substances under
the laws of the state in which the
practitioner engages in professional
3 Although there is no date on RFAA EX 7, the
Government represented in its RFAA that EX 7
shows Registrant’s pharmacy permit ‘‘continues to
be suspended.’’ RFAA, at 3.
4 Under the Administrative Procedure Act, an
agency ‘‘may take official notice of facts at any stage
in a proceeding—even in the final decision.’’
United States Department of Justice, Attorney
General’s Manual on the Administrative Procedure
Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint
1979). Pursuant to 5 U.S.C. 556(e), ‘‘[w]hen an
agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a
party is entitled, on timely request, to an
opportunity to show the contrary.’’ Accordingly,
Applicant may dispute my finding by filing a
properly supported motion for reconsideration of
finding of fact within fifteen calendar days of the
date of this Order. Any such motion shall be filed
with the Office of the Administrator and a copy
shall be served on the Government. In the event
Applicant files a motion, the Government shall
have fifteen calendar days to file a response. Any
such motion and response shall be filed and served
by email on the other party at the email address the
party submitted for receipt of communications
related to this administrative proceeding, and on
the Office of the Administrator, Drug Enforcement
Administration at dea.addo.attorneys@
dea.usdoj.gov.
VerDate Sep<11>2014
00:34 Dec 11, 2020
Jkt 253001
practice is a fundamental condition for
obtaining and maintaining a
practitioner’s registration. See, e.g.,
James L. Hooper, M.D., 76 FR 71,371
(2011), pet. for rev. denied, 481 F. App’x
826 (4th Cir. 2012); Frederick Marsh
Blanton, M.D., 43 FR 27,616, 27,617
(1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a pharmacy . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which . . . [it] practices . . . , to
distribute, dispense, . . . [or] administer
. . . a controlled substance in the
course of professional practice.’’ 21
U.S.C. 802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the CSA,
the Agency has repeatedly stated that
revocation of a practitioner’s registration
is the appropriate sanction whenever it
is no longer authorized to dispense
controlled substances under the laws of
the state in which she practices. See,
e.g., James L. Hooper, M.D., 76 FR at
71,371–72; Sheran Arden Yeates, M.D.,
71 FR 39,130, 39,131 (2006); Dominick
A. Ricci, M.D., 58 FR 51,104, 51,105
(1993); Bobby Watts, M.D., 53 FR
11,919, 11,920 (1988); Frederick Marsh
Blanton, M.D., 43 FR at 27,617.
According to Maryland statute, ‘‘a
person shall be registered by the
[Maryland] Department [of Health]
before the person manufactures,
distributes, or dispenses a controlled
dangerous substance in the State.’’ 5 Md.
Code Ann., Crim. Law § 5–301(a)(1)
(West, Westlaw current through all
legislation from the 2020 Regular
Session of the General Assembly). Also
according to Maryland statute, a
‘‘person shall hold a pharmacy permit
issued by the (Maryland State) Board (of
Pharmacy) before the person may
establish or operate a pharmacy in this
State.’’ Md. Code Ann., Health. Occ.
§ 12–401(a) (West, Westlaw current
through all legislation from the 2020
Regular Session of the General
Assembly). Accordingly, holding a
5 ‘‘Dispense,’’ under Maryland statute, means ‘‘to
deliver to the ultimate user . . . by or in accordance
with the lawful order of an authorized provider.’’
Md. Code Ann., Crim. Law § 5–101(l)(1) (West,
Westlaw current through all legislation from the
2020 Regular Session of the General Assembly).
PO 00000
Frm 00201
Fmt 4703
Sfmt 4703
permit issued by the MBP is a
prerequisite to operating a pharmacy
and dispensing a controlled substance
in Maryland.
Here, the undisputed evidence in the
record is that Registrant’s pharmacy
permit is currently suspended. In
Maryland, as already discussed, a
pharmacy must hold a permit from the
MBP to dispense a controlled substance
lawfully. Md. Code Ann., Health. Occ.
§ 12–401(a); Md. Code Ann., Crim. Law
§ 5–301(a)(1). Registrant currently lacks
a pharmacy permit in Maryland and,
thus, it is not eligible to dispense
controlled substances in Maryland. 21
U.S.C. 824(a)(3). Accordingly, I will
order that Registrant’s DEA registration
be revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. FP3109027 issued to
Poplar Grove Pharmacy Inc. This Order
is effective January 11, 2021.
Timothy J. Shea,
Acting Administrator.
[FR Doc. 2020–27234 Filed 12–10–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Ernesto C. Torres, M.D.; Decision and
Order
On July 20, 2020, the Acting Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (hereinafter,
Government or DEA), issued an Order to
Show Cause (hereinafter, OSC) to
Ernesto C. Torres, M.D., (hereinafter,
Registrant), of Frederick, Maryland.
Government’s Request for Final Agency
Action (hereinafter, RFAA) Exhibit
(hereinafter RFAAX) 4 (OSC), at 1. The
OSC proposed the revocation of
Registrant’s Certificate of Registration
No. AT8751213. Id. It alleged that
Registrant is without ‘‘authority to
handle controlled substances in
Maryland, the state in which [Registrant
is] registered with DEA.’’ Id. at 2 (citing
21 U.S.C. § 824(a)(3)).
Specifically, the OSC alleged that
‘‘[o]n January 6, 2020, the [Maryland
Board of Physicians (hereinafter, MBP)]
issued [a] Final Decision and Order on
Order for Summary Suspension,
whereby the MBP affirmed its May 2019
suspension ruling. Moreover, during the
pendency of the above MBP suspension
proceedings, [Registrant’s] state medical
license expired on September 30, 2019,
E:\FR\FM\11DEN1.SGM
11DEN1
Agencies
[Federal Register Volume 85, Number 239 (Friday, December 11, 2020)]
[Notices]
[Pages 80189-80190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-27234]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Poplar Grove Pharmacy Inc.;
Decision and Order
On November 20, 2019, the Assistant Administrator, Diversion
Control Division, Drug Enforcement Administration (hereinafter, DEA or
Government), issued an Order to Show Cause (hereinafter, OSC) to Poplar
Grove Pharmacy Inc. (hereinafter, Registrant) of Baltimore, Maryland.
OSC, at 1. The OSC proposed the revocation of Registrant's Certificate
of Registration No. FP3109027. Id. It alleged that Registrant ``has no
state authority to handle controlled substances.'' Id. (citing 21
U.S.C. 824(a)(3)).
Specifically, the OSC alleged that, ``[o]n April 15, 2019, the
Maryland State Board of Pharmacy (hereinafter, MBP) . . . issued an
Order for Summary Suspension, suspending . . . [Registrant's] Maryland
pharmacy permit.'' OSC, at 2. The OSC alleged that ``[c]onsequently,
the DEA must revoke . . . [Registrant's] DEA registration based on . .
. [its] lack of authority to handle controlled substances in the State
of Maryland.'' Id.
The OSC notified Registrant of the right to request a hearing on
the allegations or to submit a written statement, while waiving the
right to a hearing, the procedures for electing each option, and the
consequences for failing to elect either option. Id. (citing 21 CFR
1301.43). The OSC also notified Registrant of the opportunity to submit
a corrective action plan. OSC, at 3 (citing 21 U.S.C. 824(c)(2)(C)).
Adequacy of Service
In a sworn Declaration, dated May 22, 2020, a DEA Diversion
Investigator assigned to the Baltimore District Office (hereinafter,
DI) stated that he accomplished personal service of the OSC on Susan
Nwoga, Registrant's registration contact, at the Maryland Correctional
Institution for Women on December 10, 2019. Request for Final Agency
Action (hereinafter, RFAA), EX 4 (DI Declaration), at 1. The DI stated
that Ms. Nwoga took the OSC. Id.
Further evidence of the adequacy of the Government's service is
Registrant's proposed Corrective Action Plan (hereinafter, CAP) dated
December 16, 2019. RFAA EX 5 (CAP), at 1. Accordingly, based on the
evidence in the RFAA and the Government's representations, I find that
the Government's service of the OSC was adequate.
Registrant's Proposed CAP
As already discussed, Registrant timely submitted a proposed CAP.
Id. In the CAP, Registrant asked that ``DEA begin an internal
investigation on it's [sic] failure to provide . . . [Ms. Nwoga] with
whistle blower protection and why when big retail pharmacies are met
with fines, the DEA set out to entrap . . . [her], a black woman who is
an American of Nigerian descent.'' Id. at 4. Ms. Nwoga ``denied all
charges'' and stated that she is ``entitled to all privileges of a
licensed pharmacist.'' \1\ Id. In the CAP, Registrant did not address
the status of its Maryland pharmacy permit, including whether the MBP
suspended it.
---------------------------------------------------------------------------
\1\ Most of Registrant's CAP concerned Ms. Nwoga's allegations
about ``the DEA's . . . failure to follow their own monitoring
policy, thus, allowing the Baltimore city streets to become flooded
with controlled narcotics.'' RFAA EX 5, at 2. The CAP stated that
she ``satisfied all the requirements of whistle blower,'' but
``[r]ather than protect . . . [her] the DEA began an illegal under
cover [sic] operation that spanned many years'' and entrapped her.
Id. at 2-3. According to the CAP, ``[t]his case is wrought with very
ugly racism, anti-feminism, and anti-immigrant overtones in the
Baltimore City DEA. The criminal case is under appeal and when
reviewed by legal experts, the experts say I will absolutely be
released from prison.'' Id. at 3.
---------------------------------------------------------------------------
I find that Registrant waived its right to a hearing and proposed a
CAP. I find that the Assistant Administrator, Diversion Control
Division, denied ``the request to discontinue or defer administrative
proceedings.'' RFAA EX 6 (Letter Denying Proposed CAP), at 1. I also
find that the Assistant Administrator concluded that ``there is no
potential modification of . . . [the proposed CAP] that could or would
alter . . . [his] decision in this regard.'' Id. I agree with the
Assistant Administrator's CAP-related decisions.
The Government forwarded its RFAA, along with the evidentiary
record, to my office on May 28, 2020. In its RFAA, the Government
represented that ``Registrant currently lacks authority to handle
controlled substances in the state of Maryland, the jurisdiction where
it was licensed as a pharmacy and where it is registered with DEA.''
RFAA, at 3. The Government requested ``a Final Order revoking
Registrant's DEA registration.'' Id. at 4.
I issue this Decision and Order based on the record submitted by
the Government in its RFAA, which constitutes the entire record before
me.\2\ 21 CFR 1301.43(e).
---------------------------------------------------------------------------
\2\ The RFAA includes Registrant's proposed CAP.
---------------------------------------------------------------------------
Findings of Fact
Registrant's DEA Registration
Registrant is the holder of DEA Certificate of Registration No.
FP3109027 at the registered address of 709 Poplar Grove Street,
Baltimore, MD 21216. RFAA, EX 1 (Certification of Registration), at 1.
Pursuant to this registration, Registrant is authorized to dispense
controlled substances in schedules II through V for the business
activity of retail pharmacy. Id. Registrant's registration ``is in a
renewal pending status until the resolution of administrative
proceedings.'' Id.
The Status of Registrant's State License and Registration
The Government submitted a certified copy of the ``Order for
Summary Suspension'' concerning Registrant's pharmacy permit No. P05639
that the MBP issued on April 15, 2019. RFAA, EX 3 (hereinafter, Summary
Suspension Order). According to the Summary Suspension Order,
Registrant's pharmacist ``pleaded guilty . . . to approximately three
hundred (300) counts that included possession with . . . [the] intent
to distribute a controlled dangerous substance, Medicaid fraud, and
theft.'' Id. at 5. The Summary Suspension Order stated that,
``[f]ollowing her conviction, Pharmacist A was ordered held in jail
until the date of her sentencing.'' Id. It also stated that Registrant
``failed to request or submit to a closing inspection by the . . .
[MBP], as required by . . . [MBP] regulations, to ensure the proper
transfer of controlled and non-controlled drug inventory and
confidential prescription records.'' Id. at 6.
After concluding that ``the public health, safety, or welfare
imperatively requires emergency action,'' the MBP ``summarily
suspended'' the permit issued to Registrant to operate as a pharmacy in
Maryland. Id. The MBP thus prohibited Registrant from operating as a
pharmacy in Maryland and ordered the immediate return of all pharmacy
permits to the MBP. Id.
The Government also submitted a MBP website screen print showing
that Registrant's pharmacy permit is
[[Page 80190]]
``suspended.'' \3\ RFAA, EX 7 (State of Maryland Board of Pharmacy
website Screen Print), at 1.
---------------------------------------------------------------------------
\3\ Although there is no date on RFAA EX 7, the Government
represented in its RFAA that EX 7 shows Registrant's pharmacy permit
``continues to be suspended.'' RFAA, at 3.
---------------------------------------------------------------------------
As already discussed, Registrant's proposed CAP did not address the
status of its Maryland pharmacy permit. As such, the Government's
record evidence that Registrant's pharmacy permit was summarily
suspended is not rebutted.
According to Maryland's online records, of which I take official
notice, Registrant's pharmacy permit is still suspended today.\4\ State
of Maryland Board of Pharmacy Web Lookup/Verification, https://mdbop.mylicense.com/Verification (last visited date of signature of
this Order).
---------------------------------------------------------------------------
\4\ Under the Administrative Procedure Act, an agency ``may take
official notice of facts at any stage in a proceeding--even in the
final decision.'' United States Department of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e),
``[w]hen an agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a party is
entitled, on timely request, to an opportunity to show the
contrary.'' Accordingly, Applicant may dispute my finding by filing
a properly supported motion for reconsideration of finding of fact
within fifteen calendar days of the date of this Order. Any such
motion shall be filed with the Office of the Administrator and a
copy shall be served on the Government. In the event Applicant files
a motion, the Government shall have fifteen calendar days to file a
response. Any such motion and response shall be filed and served by
email on the other party at the email address the party submitted
for receipt of communications related to this administrative
proceeding, and on the Office of the Administrator, Drug Enforcement
Administration at [email protected].
---------------------------------------------------------------------------
In sum, there is no record evidence rebutting the evidence the
Government submitted with its RFAA, EX 3 and EX 7, and the evidence
from today's Maryland online records supports the Government's
evidence. Accordingly, I find that Registrant's Maryland pharmacy
permit is currently suspended.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823 of the CSA
``upon a finding that the registrant . . . has had his State license or
registration suspended . . . [or] revoked . . . by competent State
authority and is no longer authorized by State law to engage in the . .
. dispensing of controlled substances.'' With respect to a
practitioner, the Agency has long stated that the possession of
authority to dispense controlled substances under the laws of the state
in which the practitioner engages in professional practice is a
fundamental condition for obtaining and maintaining a practitioner's
registration. See, e.g., James L. Hooper, M.D., 76 FR 71,371 (2011),
pet. for rev. denied, 481 F. App'x 826 (4th Cir. 2012); Frederick Marsh
Blanton, M.D., 43 FR 27,616, 27,617 (1978).
This rule derives from the text of two provisions of the CSA.
First, Congress defined the term ``practitioner'' to mean ``a pharmacy
. . . or other person licensed, registered, or otherwise permitted, by
. . . the jurisdiction in which . . . [it] practices . . . , to
distribute, dispense, . . . [or] administer . . . a controlled
substance in the course of professional practice.'' 21 U.S.C. 802(21).
Second, in setting the requirements for obtaining a practitioner's
registration, Congress directed that ``[t]he Attorney General shall
register practitioners . . . if the applicant is authorized to dispense
. . . controlled substances under the laws of the State in which he
practices.'' 21 U.S.C. 823(f). Because Congress has clearly mandated
that a practitioner possess state authority in order to be deemed a
practitioner under the CSA, the Agency has repeatedly stated that
revocation of a practitioner's registration is the appropriate sanction
whenever it is no longer authorized to dispense controlled substances
under the laws of the state in which she practices. See, e.g., James L.
Hooper, M.D., 76 FR at 71,371-72; Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A. Ricci, M.D., 58 FR 51,104, 51,105
(1993); Bobby Watts, M.D., 53 FR 11,919, 11,920 (1988); Frederick Marsh
Blanton, M.D., 43 FR at 27,617.
According to Maryland statute, ``a person shall be registered by
the [Maryland] Department [of Health] before the person manufactures,
distributes, or dispenses a controlled dangerous substance in the
State.'' \5\ Md. Code Ann., Crim. Law Sec. 5-301(a)(1) (West, Westlaw
current through all legislation from the 2020 Regular Session of the
General Assembly). Also according to Maryland statute, a ``person shall
hold a pharmacy permit issued by the (Maryland State) Board (of
Pharmacy) before the person may establish or operate a pharmacy in this
State.'' Md. Code Ann., Health. Occ. Sec. 12-401(a) (West, Westlaw
current through all legislation from the 2020 Regular Session of the
General Assembly). Accordingly, holding a permit issued by the MBP is a
prerequisite to operating a pharmacy and dispensing a controlled
substance in Maryland.
---------------------------------------------------------------------------
\5\ ``Dispense,'' under Maryland statute, means ``to deliver to
the ultimate user . . . by or in accordance with the lawful order of
an authorized provider.'' Md. Code Ann., Crim. Law Sec. 5-101(l)(1)
(West, Westlaw current through all legislation from the 2020 Regular
Session of the General Assembly).
---------------------------------------------------------------------------
Here, the undisputed evidence in the record is that Registrant's
pharmacy permit is currently suspended. In Maryland, as already
discussed, a pharmacy must hold a permit from the MBP to dispense a
controlled substance lawfully. Md. Code Ann., Health. Occ. Sec. 12-
401(a); Md. Code Ann., Crim. Law Sec. 5-301(a)(1). Registrant
currently lacks a pharmacy permit in Maryland and, thus, it is not
eligible to dispense controlled substances in Maryland. 21 U.S.C.
824(a)(3). Accordingly, I will order that Registrant's DEA registration
be revoked.
Order
Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21
U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No.
FP3109027 issued to Poplar Grove Pharmacy Inc. This Order is effective
January 11, 2021.
Timothy J. Shea,
Acting Administrator.
[FR Doc. 2020-27234 Filed 12-10-20; 8:45 am]
BILLING CODE 4410-09-P